12.79 USD
-0.04 (-0.31%)
12.79 USD
0 (0%)
We assign a fundamental rating of 3 out of 10 to NEO. NEO was compared to 102 industry peers in the Health Care Providers & Services industry. The financial health of NEO is average, but there are quite some concerns on its profitability. While showing a medium growth rate, NEO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
- In the past year NEO was profitable.
- In the past year NEO had a positive cash flow from operations.
- NEO had negative earnings in 4 of the past 5 years.
- In multiple years NEO reported negative operating cash flow during the last 5 years.
1.2 Ratios
- With a Return On Assets value of -8.25%, NEO is not doing good in the industry: 68.63% of the companies in the same industry are doing better.
- The Return On Equity of NEO (-13.54%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.25% | ||
| ROE | -13.54% | ||
| ROIC | N/A |
ROA(3y)-6.11%
ROA(5y)-3.67%
ROE(3y)-10.84%
ROE(5y)-6.53%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- NEO has a better Gross Margin (43.46%) than 72.55% of its industry peers.
- In the last couple of years the Gross Margin of NEO has declined.
- The Profit Margin and Operating Margin are not available for NEO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.46% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.37%
GM growth 5Y-1.82%
2. Health
2.1 Basic Checks
- NEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
- NEO has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, NEO has more shares outstanding
- NEO has a worse debt/assets ratio than last year.
2.2 Solvency
- NEO has an Altman-Z score of 1.96. This is not the best score and indicates that NEO is in the grey zone with still only limited risk for bankruptcy at the moment.
- With a Altman-Z score value of 1.96, NEO perfoms like the industry average, outperforming 46.08% of the companies in the same industry.
- NEO has a Debt/Equity ratio of 0.41. This is a healthy value indicating a solid balance between debt and equity.
- With a decent Debt to Equity ratio value of 0.41, NEO is doing good in the industry, outperforming 65.69% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.96 |
ROIC/WACCN/A
WACC7.87%
2.3 Liquidity
- A Current Ratio of 3.91 indicates that NEO has no problem at all paying its short term obligations.
- NEO's Current ratio of 3.91 is amongst the best of the industry. NEO outperforms 90.20% of its industry peers.
- NEO has a Quick Ratio of 3.62. This indicates that NEO is financially healthy and has no problem in meeting its short term obligations.
- With an excellent Quick ratio value of 3.62, NEO belongs to the best of the industry, outperforming 90.20% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.62 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an nice 11.11% over the past year.
- Measured over the past years, NEO shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -20.25% on average per year.
- The Revenue has grown by 10.10% in the past year. This is quite good.
- Measured over the past years, NEO shows a quite strong growth in Revenue. The Revenue has been growing by 10.07% on average per year.
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5Y-20.25%
EPS Q2Q%-40%
Revenue 1Y (TTM)10.1%
Revenue growth 3Y10.9%
Revenue growth 5Y10.07%
Sales Q2Q%11.9%
3.2 Future
- Based on estimates for the next years, NEO will show a very strong growth in Earnings Per Share. The EPS will grow by 41.92% on average per year.
- Based on estimates for the next years, NEO will show a quite strong growth in Revenue. The Revenue will grow by 9.49% on average per year.
EPS Next Y-12.21%
EPS Next 2Y27.95%
EPS Next 3Y53.99%
EPS Next 5Y41.92%
Revenue Next Year9.58%
Revenue Next 2Y9.72%
Revenue Next 3Y9.54%
Revenue Next 5Y9.49%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 127.90, which means the current valuation is very expensive for NEO.
- NEO's Price/Earnings ratio is in line with the industry average.
- Compared to an average S&P500 Price/Earnings ratio of 27.38, NEO is valued quite expensively.
- The Price/Forward Earnings ratio is 78.13, which means the current valuation is very expensive for NEO.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of NEO is on the same level as its industry peers.
- Compared to an average S&P500 Price/Forward Earnings ratio of 24.29, NEO is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 127.9 | ||
| Fwd PE | 78.13 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- NEO's earnings are expected to grow with 53.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.95%
EPS Next 3Y53.99%
5. Dividend
5.1 Amount
- No dividends for NEO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
12.79
-0.04 (-0.31%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)01-12 2026-01-12/amc
Earnings (Next)04-27 2026-04-27/bmo
Inst Owners102.56%
Inst Owner Change0.61%
Ins Owners1.14%
Ins Owner Change1.18%
Market Cap1.65B
Revenue(TTM)709.16M
Net Income(TTM)-113.47M
Analysts72.22
Price Target13.54 (5.86%)
Short Float %6.56%
Short Ratio3.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.29%
Min EPS beat(2)31.6%
Max EPS beat(2)40.97%
EPS beat(4)4
Avg EPS beat(4)51.9%
Min EPS beat(4)31.6%
Max EPS beat(4)100%
EPS beat(8)8
Avg EPS beat(8)207.03%
EPS beat(12)12
Avg EPS beat(12)159.81%
EPS beat(16)16
Avg EPS beat(16)125.04%
Revenue beat(2)1
Avg Revenue beat(2)-0.28%
Min Revenue beat(2)-1.73%
Max Revenue beat(2)1.18%
Revenue beat(4)1
Avg Revenue beat(4)-1.22%
Min Revenue beat(4)-2.68%
Max Revenue beat(4)1.18%
Revenue beat(8)4
Avg Revenue beat(8)-0.08%
Revenue beat(12)8
Avg Revenue beat(12)2.05%
Revenue beat(16)10
Avg Revenue beat(16)1.77%
PT rev (1m)7.66%
PT rev (3m)38.44%
EPS NQ rev (1m)-0.21%
EPS NQ rev (3m)-12.64%
EPS NY rev (1m)-1.15%
EPS NY rev (3m)-4.56%
Revenue NQ rev (1m)-0.1%
Revenue NQ rev (3m)-0.28%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 127.9 | ||
| Fwd PE | 78.13 | ||
| P/S | 2.33 | ||
| P/FCF | N/A | ||
| P/OCF | 121.19 | ||
| P/B | 1.97 | ||
| P/tB | 83.65 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.1
EY0.78%
EPS(NY)0.16
Fwd EY1.28%
FCF(TTM)-0.13
FCFYN/A
OCF(TTM)0.11
OCFY0.83%
SpS5.48
BVpS6.48
TBVpS0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.82
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.25% | ||
| ROE | -13.54% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.46% | ||
| FCFM | N/A |
ROA(3y)-6.11%
ROA(5y)-3.67%
ROE(3y)-10.84%
ROE(5y)-6.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.37%
GM growth 5Y-1.82%
F-Score4
Asset Turnover0.52
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.41 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 44.15% | ||
| Cap/Sales | 4.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.91 | ||
| Quick Ratio | 3.62 | ||
| Altman-Z | 1.96 |
F-Score4
WACC7.87%
ROIC/WACCN/A
Cap/Depr(3y)46.9%
Cap/Depr(5y)68.48%
Cap/Sales(3y)5.71%
Cap/Sales(5y)7.39%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)11.11%
EPS 3YN/A
EPS 5Y-20.25%
EPS Q2Q%-40%
EPS Next Y-12.21%
EPS Next 2Y27.95%
EPS Next 3Y53.99%
EPS Next 5Y41.92%
Revenue 1Y (TTM)10.1%
Revenue growth 3Y10.9%
Revenue growth 5Y10.07%
Sales Q2Q%11.9%
Revenue Next Year9.58%
Revenue Next 2Y9.72%
Revenue Next 3Y9.54%
Revenue Next 5Y9.49%
EBIT growth 1Y-6.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year146.43%
EBIT Next 3Y41.59%
EBIT Next 5Y28.43%
FCF growth 1Y65.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y158.31%
OCF growth 3YN/A
OCF growth 5Y-21.37%
NEOGENOMICS INC / NEO FAQ
What is the fundamental rating for NEO stock?
ChartMill assigns a fundamental rating of 3 / 10 to NEO.
What is the valuation status for NEO stock?
ChartMill assigns a valuation rating of 1 / 10 to NEOGENOMICS INC (NEO). This can be considered as Overvalued.
How profitable is NEOGENOMICS INC (NEO) stock?
NEOGENOMICS INC (NEO) has a profitability rating of 1 / 10.
Can you provide the expected EPS growth for NEO stock?
The Earnings per Share (EPS) of NEOGENOMICS INC (NEO) is expected to decline by -12.21% in the next year.